TRACON Pharmaceuticals, Inc. (TCON)

NASDAQ: TCON · IEX Real-Time Price · USD
1.67
-0.06 (-3.47%)
Feb 3, 2023, 4:00 PM EST - Market closed
-3.47%
Market Cap 37.09M
Revenue (ttm) n/a
Net Income (ttm) -29.85M
Shares Out 22.21M
EPS (ttm) -1.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 82,458
Open 1.72
Previous Close 1.73
Day's Range 1.67 - 1.75
52-Week Range 1.10 - 3.00
Beta 1.34
Analysts Buy
Price Target 9.52 (+470.06%)
Earnings Date Mar 21, 2023

About TCON

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelio... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 30, 2015
Employees 19
Stock Exchange NASDAQ
Ticker Symbol TCON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for TCON stock is "Buy." The 12-month stock price forecast is $9.52, which is an increase of 470.06% from the latest price.

Price Target
$9.52
(470.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023

Initial $3.5M Funding Maintains Cash Runway of Mid-2023 Initial $3.5M Funding Maintains Cash Runway of Mid-2023

1 month ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial

Objective Response Rate (ORR) by Central Review Achieved in Each Cohort at Interim Efficacy Analysis that Exceeded the Futility Threshold

1 month ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

2 months ago - GlobeNewsWire

TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

2 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from ENVASARC Phase 2 Pivotal Trial - Trial to Proceed as Planned

Review of Interim Efficacy Data by IDMC to Occur in Fourth Quarter Review of Interim Efficacy Data by IDMC to Occur in Fourth Quarter

4 months ago - GlobeNewsWire

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN) stock, a biotech firm working on a promising Alzheimer's therapy.

4 months ago - InvestorPlace

TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS

SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pl...

5 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital

Initial $10 million draw extends cash runway to mid-2023 Initial $10 million draw extends cash runway to mid-2023

5 months ago - GlobeNewsWire

US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

BEIJING & SAN DIEGO--(BUSINESS WIRE)-- #Biocytogen--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S....

5 months ago - Business Wire

TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

SAN DIEGO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

5 months ago - GlobeNewsWire

TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

6 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

6 months ago - GlobeNewsWire

TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform ...

6 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

6 months ago - GlobeNewsWire

4 Stocks Under $2 Insiders Are Aggressively Buying: NEXGEL, eFFECTOR Therapeutics And More

U.S. crude oil futures traded higher by over 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: EFTRNXGL
7 months ago - Benzinga

TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer...

8 months ago - GlobeNewsWire

TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...

9 months ago - GlobeNewsWire

TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ca...

9 months ago - GlobeNewsWire

Follow the Insiders and Buy the Dip in These 3 Stocks

These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.

Other symbols: ENTXLGVN
9 months ago - InvestorPlace

TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022

SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...

9 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K.

Expects to Report Results of Independent Data Monitoring Committee (IDMC) Mandated Interim Safety Reviews and Interim Efficacy Review in the Second Half of 2022 Expects to Report Results of Independen...

10 months ago - GlobeNewsWire

Recession Fears are Creating a Golden Opportunity for Biotech Stocks

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech S...

10 months ago - InvestorPlace

TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth Conference

SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cance...

11 months ago - GlobeNewsWire

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

Announced FDA Approval of Amended ENVASARC Protocol, ENVASARC Interim Efficacy Data on Track for 2H22 Initiating combination trial of proprietary CTLA-4 with envafolimab in 2022

11 months ago - GlobeNewsWire